High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients
暂无分享,去创建一个
A. Sapino | T. Venesio | A. Pisacane | M. Aglietta | A. Zaccagna | U. Miglio | F. Carnevale-Schianca | S. Gallo | D. Caravelli | A. Balsamo | P. Becco | E. Berrino | L. Paruzzo | S. Poletto | C. Debernardi | P. Rescigno | C. Piccinelli
[1] K. Jang,et al. Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. , 2020, ESMO open.
[2] P. Ascierto,et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.
[3] P. Dundr,et al. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants , 2019, Scientific Reports.
[4] M. Denis,et al. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay , 2019, PloS one.
[5] E. Raso,et al. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma , 2019, BMC Cancer.
[6] J. Eshleman,et al. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing , 2019, BMC Cancer.
[7] G. Orchard,et al. Immunohistochemical detection of V600E BRAF mutation is a useful primary screening tool for malignant melanoma , 2019, British journal of biomedical science.
[8] P. Ulivi,et al. Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? , 2018, International journal of molecular sciences.
[9] L. Carvalho,et al. Heterogeneity in Lung Cancer , 2018, Pathobiology.
[10] S. Mocellin,et al. BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors , 2018, Molecular Cancer Therapeutics.
[11] G. Turashvili,et al. Tumor Heterogeneity in Breast Cancer , 2017, Front. Med..
[12] Liang Cheng,et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine , 2017, Modern Pathology.
[13] G. McArthur,et al. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma , 2017, British Journal of Cancer.
[14] E. Amir,et al. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer , 2017, British Journal of Cancer.
[15] C. Berking,et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care , 2017, BMC Cancer.
[16] M. Millward,et al. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma , 2017, Pigment cell & melanoma research.
[17] J. Wilmott,et al. BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting , 2016, Histopathology.
[18] J. Garioch,et al. A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma , 2016, British Journal of Cancer.
[19] L. Akslen,et al. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival , 2016, British Journal of Cancer.
[20] C. Berking,et al. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma , 2015, Oncotarget.
[21] Alison White,et al. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor , 2015, Pathology.
[22] J. Mosser,et al. Prognostic and predictive values of oncogenic BRAF, NRAS, c‐KIT and MITF in cutaneous and mucous melanoma , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[23] J. Emile,et al. Variations of BRAF mutant allele percentage in melanomas , 2015, BMC Cancer.
[24] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[25] Soo-Nyung Kim,et al. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. , 2015, Journal of the American Academy of Dermatology.
[26] Parisha Bhatia,et al. Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. , 2015, Annals of translational medicine.
[27] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[28] R. Porcher,et al. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma. , 2014, Melanoma research.
[29] A. Eggermont,et al. Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site , 2014, Annals of Surgical Oncology.
[30] Jacqueline A. L. MacArthur,et al. Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants , 2013, Nucleic Acids Res..
[31] L. Heinzerling,et al. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations , 2013, British Journal of Cancer.
[32] H. Kaufman,et al. Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions , 2013, American Journal of Clinical Dermatology.
[33] M. Mazumdar,et al. Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma , 2012, PloS one.
[34] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[35] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[36] R. Scolyer,et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.
[37] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[38] C. Petti,et al. In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation , 2008, Modern Pathology.
[39] R. Millikan,et al. Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma , 2007, Cancer Epidemiology Biomarkers & Prevention.
[40] J. Lundeberg,et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.
[41] G. Saldanha,et al. Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies , 2006, Clinical Cancer Research.
[42] J. McCubrey,et al. Detection of BRAF gene mutation in primary choroidal melanoma tissue , 2006, Cancer biology & therapy.
[43] L. Kanter,et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[45] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.